Canada – Taiwan Life Science Forum: Digital and Precision Health, Infection Control

Synopsis:

Canada’s life sciences industry has more than 1000 companies with $2.4 Billion+ R&D and $87.4 Billion revenues. Canada has strong strengths as an emerging leader in health AI, precision medicine, regenerative medicine, genomics & oncology, and also embraces other emerging trends of artificial intelligence, digital health, gene editing and infection control. Canada, as the 8th largest medical device market and 9th largest pharmaceutical market, has 40 world class research hospitals, 17 life science networks/excellence centers, 800 drug products in the pipeline and 60+ incubators & accelerators supporting the life science industry development.

Canadian Trade Office in Taipei (CTOT) co-organizes with Taiwan Bio Industries Organisation (TBIO), Alberta Taiwan Office and British Columbia Taiwan Office on this Canada-Taiwan Life Science Forum during 2023 Bio Asia Taiwan week. Four Canadian companies and organisation with cutting-edge and innovation technology will be introduced to you in the post-COVID era!

Date / Time:Wednesday, July 26, 2023 ｜ 13:30–17:00 pm (Taipei Time)

Venue:Room 702, 7F, TaiNEX 2 / 南港展覽館2館7樓702室 (Address: No.2, Jingmao 2nd Rd., Nangang District, Taipei City 11568, Taiwan /地址: 115台北市南港區經貿二路2號)

Co-organizer: Taiwan Bio Industries Organization, Alberta Taiwan Office

Language: English

Registration: https://reurl.cc/8jb117

• 此為免費研討會，由於座位有限，主辦單位保有確認報名的權益，敬請見諒。
• 會中將提供與會者簡便茶點。

Agenda

Japanese Companies: Your Promising Partners

Synopsis:

Japan has one of the most active biotechnology industries in the world, as evidenced by the large number of patent applications. Every day, many pharmaceutical, chemical, healthcare and food companies, from startups to large corporations, are applying various kinds of biotechnologies to their R&Ds to develop novel products.

As seen in the examples of pharmaceutical development, it has increasingly become difficult for a single company to develop products by itself in recent years, leading to the increases in the opportunities for external collaboration in the areas of R&D and manufacturing. Those current streams enhance the importance of bioecosystems, which include open innovation and outsourced manufacturing for companies along with the funding supports for startups. The government of Japan has released the Bioeconomy Strategy in 2019, concentrating on the formation of bioecosystems, and Japanese academia, local governments and bioindustries are now extensively working with this strategy.

In light of this circumstances, we have planned this session to introduce current situation of bioecosystems in Japan and leading three Japanese companies, global pharmaceutical company, CDMO and VC, aggressive especially in collaborating with Taiwan bioindustry players, and will have their presentations about their strategies and plans for the collaboration or investment.

We hope that this session will help you accelerate collaborations with Japanese companies.

Date / Time:Thursday, July 27, 2023 ｜ 14:00–15:20 pm (Taipei Time)

Venue:Room 404, 4F, TaiNEX 1 (南港展覽館一館，4樓404會議室)

Co-organizer: Japan Bioindustry Association

Session Chairs: Prof. Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association

Language: English

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

Choose Malaysia – Your One-Stop Sourcing Partner

Malaysia is a strong contributor in providing essential solutions to the global life-sciences and medical technology industry, which is gaining traction in a post-pandemic world. Malaysia is committed to improving healthcare delivery standards to provide world-class medical products and technologies. The session showcases insights of Malaysia’s capabilities in areas related to the medical devices, pharmaceutical and biotechnology industries.

Date / Time:Thursday, July 27, 2023 ｜ 13:30–17:00 pm (Taipei Time)

Venue:Room 402C, 4F, TaiNEX 1 (南港展覽館一館，4樓402C會議室)

Hosted by: Malaysian Friendship and Trade Centre, Taipei
Organized by: Malaysian Friendship and Trade Centre, Taipei (Trade Division)
Supported by: Biotechnology & Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs

Language: English

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

Australia – Taiwan Clinical Trials and Biotech Forum

Austrade’s Taiwan Office, the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and the Taiwan BIO Industry Association cordially invite you to join our Australia-Taiwan Clinical Trials and Biotech Forum on 28^th July. 
Australia is a go-to destination for conducting clinical trials.  Companies can leverage our advance capabilities in quality, speed and cost.   You will hear from leading clinical trials related service providers and innovative biotech companies from Australia and Taiwan to share their experience and insights in conducting clinical trials in Australia and developing their novel therapies.  
Please join us at the forum and have one-on-one meetings with these companies.   The Forum will be conducted in English, with registrations closing Friday 21 July 2023.

Date / Time: Friday, July 28, 2023  08:30-16:30

Venue: Room 402C, 4F, Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1) (南港展覽館一館4樓402C會議室)

Co-Organized by: Austrade Taiwan, BPIPO, Taiwan Bio Industry Organization

Language: English

Registration: https://forms.gle/eUZbuPUR7BujLr8D6

Agenda

Taiwan Session

Date / Time: Friday, July 28, 2023 13:30-16:00

Venue: Room 404, 4F, Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1) (南港展覽館一館4樓404會議室)

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

Hong Kong Session

Date / Time: Friday, July 28, 2023 ｜ 9:00–10:10 pm (Taipei Time)
Venue: Room 404, 4F, TaiNEX 1
Co-organizer: Hong Kong Biotechnology Organization
Language: English
Registration: ttps://forms.gle/cEDJYd5pGkhFphbN9

Agenda

Lithuania – your gateway to Europe

Lithuania, a small Baltic nation with a population of around 2.8 million people, has shifted its focus to Life Sciences. In this session, governmental agency responsible for attracting foreign direct investment to the country - Invest Lithuania’s, Head of Life Sciences team Karolina Karl will discuss Lithuania’s journey to becoming an independent state driven by innovation and how Life Sciences are seen as a key part of the national strategy for future economic growth. With this aim, the government set an ambitious goal to increase the GDP contribution of the Life Sciences industry from 2.5% to 5% by 2030.

To date, Lithuania has built a well-functioning business ecosystem where it takes only a few days to register a biotech company or get construction permits, all through digitalized systems aligned with EU regulations and norms. The Baltic champion also offers some of the most competitive FDI tax incentives in Europe, including one of the lowest patent box tax as well as 20 years corporate profit tax release for large scale investments. Multinational companies including Thermo Fisher, Hollister, Dexcom, Esco, Teva and others have already taken advantage of the unbeatable conditions and world-class talent pool available locally.

This session will illustrate what Lithuania can offer through stories covering the research of a local Vilnius University Professor Virginijus Siksnys, who was one of the co-founders of the CRISPR Cas9 technology, alongside Nobel Prize winners Emmanuelle Charpentier and Jennifer A. Doudna. In addition to that, you will get to know what drug was developed by Teva’s Lithuanian team and how Thermo Fisher has been growing in the market for the last 20 years.

Come and explore a new gateway to Europe!

Date / Time: On-demand

Venue:Online Event Platform

Organizer:The Lithuanian Investment Promotion Agency - Invest Lithuania, Taiwan Bio Industry Organization

Session Speaker:Mrs. Karolina Karl – Head of Life Sciences team, Invest Lithuania

Registration:https://bioasiataiwan.com/en/registration/plan